Pharmacist independent prescribing reaches NHS community pharmacy in England this autumn, just as the first cohort of pharmacists trained to prescribe from registration enters the workforce.
Pharma and medtech teams that understand where pharmacist prescribing happens, and how to support the people doing it, will be well placed to help the NHS make the most of this workforce.
This summer, most pharmacists joining the register in Great Britain did so as qualified independent prescribers, the first cohort trained to prescribe within their degree and foundation year. From this autumn, community pharmacies in England can put that qualification to work within Pharmacy First, including five conditions that only a pharmacist prescriber can treat. The profession already has 22,770 pharmacist independent prescribers, a third of all registered pharmacists, and several thousand more will join each year. Industry has long worked with community pharmacy around supply and dispensing. A large prescribing workforce is now forming on the high street, and the NHS is still designing many of the services it will deliver.
The 2026/27 Community Pharmacy Contractual Framework (CPCF) sets total funding at £3.636 billion, an increase of £340 million, or 10.3%, on the previous year. Its most significant change is a national independent prescribing offer, introduced from autumn 2026 as an extension of Pharmacy First and the Pharmacy Contraception Service.
Under the new arrangements, NHS-authorised pharmacist prescribers can:
These sit alongside the seven original Pharmacy First conditions, which include sore throat, sinusitis and uncomplicated urinary tract infections.
Funding comes through a £500 set-up fee, a £525 monthly infrastructure payment for pharmacies that make a prescriber available for at least 24 hours a week, and consultation fees of £17 to £25. NHS England estimates the five new conditions could account for two to three million consultations a year once the service is fully established, and is making £51,000 available to each integrated care board (ICB) to support rollout. Participating pharmacies are expected to show prescribing activity in NHS prescribing data by March 2027.
According to the Nuffield Trust’s April 2026 report on independent prescribing, the UK has more than 98,000 non-medical independent prescribers, of whom 22,770 are pharmacists. With MPharm intakes above 4,000 students a year for the past four years, and prescribing now built into initial education and training, several thousand newly qualified pharmacist prescribers will enter the workforce each year from 2026.
That changes the reach of prescribing across the community network. England had 10,526 community pharmacies in February 2026. The National Pharmacy Association (NPA) projects that 75% of pharmacies could have a pharmacist prescriber within three to five years, and that by 2031 there will be enough prescribers for every pharmacy in England to have at least one.
The General Pharmaceutical Council (GPhC) published advice for newly qualified prescribing pharmacists in June 2026, covering practice within competence, mentorship and support, indemnity and the working environment employers should provide.
Holding a prescribing qualification and using it are separate steps, and the evidence so far shows a gap between them in community pharmacy. A 2024 Pharmaceutical Journal survey found that 14% of community pharmacist respondents were prescribers, against 53% in hospitals and 71% in general practice. Among the community prescribers, 26% had never prescribed, and 70% cited lack of opportunity as the main barrier.
The NHS’s own pilots show what closing that gap requires. The University of Manchester’s evaluation of the Independent Prescribing Pathfinder Programme, published in January 2026 and covering around 200 sites, identified five conditions for success:
Pharmacists in the Pathfinder Programme reported higher job satisfaction, and some said the programme had kept them in the profession. The evaluation also recorded practical barriers, including read-only access to GP records, difficulty arranging indemnity cover and the need for predictable patient volumes to make services viable.
The Nuffield Trust report raises related concerns about limited supervision in community pharmacy, a shortage of designated prescribing practitioners and a lack of protected development time. Community Pharmacy England (CPE) agreed the overall 2026/27 settlement but has reservations about the prescribing element. In its words:
“We are not persuaded that sufficient investment is being made.”
CPE has also described the interim IT arrangements, which initially support a single electronic prescription system, as “far from ideal”. These issues will shape how quickly pharmacies sign up and how many qualified prescribers find regular prescribing work in community settings.
The five national prescribing-only conditions are acute and self-limiting. The NHS 10 Year Health Plan sets the longer-term direction, expecting community pharmacists to take a growing role in managing long-term conditions and complex medicine regimes, including obesity, high blood pressure and high cholesterol. The plan calls for the pharmacy contract to be reformed so that pharmacist prescribing can be commissioned within clinical pathways, for pharmacists to be embedded in neighbourhood health centres and ICBs, and for pharmacies to connect to the Single Patient Record.
The Pathfinder Programme has already tested much of this. Its sites covered cardiovascular disease, respiratory conditions, women’s health and menopause, deprescribing and antidepressant reviews, and found that collaboration between pharmacist prescribers and GP practices was essential for long-term condition models. Until national reform arrives, local commissioning by ICBs is the most likely route for these services, which means provision will vary from one area to the next. It also aligns with the NHS’s wider push to find and treat people with undiagnosed cardiovascular risk, which CHASE covered in its analysis of the CVD framework.
Many of the pharmacists prescribing in community settings over the next five years will be early in their careers. The GPhC’s advice places mentorship and support at the centre of safe practice for this group, and the Nuffield Trust identifies gaps in exactly that area. Industry already supports clinical education for other prescribing professions. Extending high-quality, non-promotional education and medical information to pharmacist prescribers, within the ABPI Code of Practice, gives companies a practical way to support safe prescribing and good patient outcomes as this workforce grows in confidence.
Pharmacist prescribers will work within national service specifications, local formularies and pathways agreed by ICB medicines optimisation teams. For long-term conditions in particular, the decisions that determine how and when a medicine is used will be made at system level. Companies that work with ICBs on pathway design, evidence and implementation support can help make sure new pharmacy services reflect current guidance from the start. The same local variation affects formulary access more broadly, which CHASE explored in its piece on the Single National Formulary.
Starting and adjusting treatment for high blood pressure or high cholesterol depends on reliable measurement and follow-up. Ambulatory blood pressure monitoring, point-of-care testing and connected digital tools all become more important as pharmacist prescribers take on more of this work, and the Pathfinder evaluation identified digital infrastructure as a condition for success. Medtech companies with proven monitoring and testing solutions have a clear role in helping community pharmacy deliver long-term condition care safely and at scale.
Coverage will be uneven for several years. Some pharmacies will have a prescriber on site most of the week, others will have none, and locally commissioned services will differ between ICBs. As participating pharmacies begin to report prescribing activity through NHS data, field and account teams will be able to see where pharmacist prescribing is established and plan engagement accordingly, alongside their work with GP practices and primary care networks.
Pharmacist independent prescribing has reached community pharmacy with a large and growing workforce behind it. The number of qualified prescribers is rising faster than the services commissioned for them, and the national pathways launching this autumn cover a narrow set of acute conditions. The larger opportunity for patients lies in long-term conditions, where the 10-Year Health Plan, the Pathfinder evidence and local commissioning all point in the same direction. For pharma and medtech, that makes community pharmacy a prescribing setting and a supply channel. Companies that support new prescribers, contribute to local pathway design and help the NHS measure what works can play a real part in making pharmacist prescribing deliver for patients.
CHASE works with pharmaceutical and medtech companies and the NHS to improve patient access to care through outsourced field teams, NHS-Industry Partnerships and market insights. Our team can help you understand how pharmacist prescribing is developing in your priority areas and how to engage with it.
Get in touch with our team to find out more about how we can help.
Pharmacist independent prescribing allows qualified pharmacists to assess patients, make diagnoses within their competence and prescribe medicines without relying on a Patient Group Direction. From summer 2026, most pharmacists joining the register in Great Britain qualify as independent prescribers, with prescribing built into their degree and foundation training.
From autumn 2026, NHS-authorised pharmacist prescribers can prescribe within existing Pharmacy First and contraception pathways and treat five new conditions: acute otitis externa, seasonal allergic rhinitis, mild to moderate acne, episodic migraine, and mild skin infections including scabies. NHS England estimates two to three million consultations a year for these conditions. These sit alongside the original seven Pharmacy First conditions: acute otitis media (ages 1 to 17), impetigo (1 and over), infected insect bites (1 and over), shingles (18 and over), sinusitis (12 and over), sore throat (5 and over), uncomplicated urinary tract infections (women aged 16 to 64).
The Nuffield Trust reports 22,770 pharmacist independent prescribers, a third of all pharmacists, and several thousand more will register each year from 2026. The National Pharmacy Association projects enough prescribers for every community pharmacy in England to have at least one by 2031.
The NHS Pathfinder Programme evaluation identified clinical governance, supervision, skill mix, digital infrastructure and viable funding as the conditions for success. Reported barriers include read-only access to patient records, difficulty arranging indemnity, limited supervision and uncertainty over whether current funding covers the workload.
The NHS 10 Year Health Plan expects community pharmacists to take a growing role in managing long-term conditions such as high blood pressure, high cholesterol and obesity. Until the Pharmacy Contract is reformed, these services are most likely to develop through local commissioning by Integrated Care Boards.
Explore our latest thinking, event updates and industry insights to stay informed.
Four new NHS pilots promise faster medicines access under the UK-US pharma deal. CHASE assesses what past funding mandates show about adoption speed.
NHS mental health commissioning is shifting from counting appointments to measuring recovery. CHASE examines what this means for pharma and medtech.
Precision medicine makes pharma and medtech convergence a commercial necessity. CHASE examines what that means for companies and the NHS in practice.
.svg)
